和邦生物(603077.SH):2021年度淨利潤預增7227.36%-7960.09%
格隆匯1月12日丨和邦生物(603077.SH)公佈2021年年度業績預增公吿,公司預計2021年年度實現歸屬於上市公司股東的淨利潤與上年同期相比,將增加29.59億元-32.59億元,同比增加7227.36%-7960.09%;預計2021年年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期相比,將增加26.21億元-29.21億元,同比增加687.36%-766.04%。
本期業績預增的主要原因系:
(一)產品銷售價格提升:公司主要產品為雙甘膦、草甘膦、純鹼、氯化銨、玻璃,受益於環保要求提升以及疫情導致的落後產能進一步出清、產能擴張受到限制,疊加下游需求增長,從而帶動銷售價格上漲,使公司能獲得合理的運營利潤。
(二)公司近幾年通過對基礎工作的梳理,進行大規模的環保、安全、產能匹配投入,帶來了在安全、環保、成本控制、穩定運行方面的優勢,使公司能按計劃實現高產、穩定運行,從而保證了銷售的穩步提升。
(三)公司不斷進行企業文化培育、提升員工素養、招聘高素質人才,使公司管理效率、執行力得到有效提升,從而保障公司的高質量運營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.